Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study

Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study

Aim: To evaluate the efficacy and safety of second-line treatment with axitinib plus toripalimab in patients with metastatic renal cell carcinoma and failure of VEGFR tyrosine kinase inhibitors. Methods: Data were collected restropectively. Kaplan-Meier analysis and Cox proportional hazards model de...

Full description

Bibliographic Details
Main Authors: Huang, J. (Author), Huang, Y. (Author), Kong, W. (Author), Shi, G. (Author), Wang, P. (Author), Wang, S. (Author), Wang, Y. (Author), Xue, W. (Author), Zhang, J. (Author)
Format: Article
Language:English
Published: Future Medicine Ltd. 2022
Subjects:
Antibodies, Monoclonal, Humanized
axitinib
Axitinib
Carcinoma, Renal Cell
China
clinical trial
efficacy
human
Humans
IMDC classification
Kidney Neoplasms
kidney tumor
monoclonal antibody
mRCC
multicenter study
pathology
PD-1
renal cell carcinoma
response rate
Retrospective Studies
retrospective study
safety
second line
toripalimab
treatment-related toxicities
VEGFR failure
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items